Stimgenics Open-Label, Post Market Study

Inclusion Criteria: 1. Be a candidate for SCS system (trial and implant) per labeled indication (back and leg pain) 2. Has an average back pain intensity ≥ 5.0 cm on the 10.0 cm Visual Analog Scale (VAS) at the time of enrollment with moderate to severe chronic leg pain 3. Be willing and capable of giving written informed consent to participate in this clinical study based on voluntary agreement after a thorough explanation of the subject's participation has been provided. 4. Be willing and capable of subjective evaluation, read and understand English-written questionnaires, and read, understand and sign the written inform consent in English. 5. Be 18 years of age or older at the time of enrollment 6. Be on a stable pain medication regime, as determined by the study investigator, for at least 30 days prior to enrolling in this study 7. Be willing to not increase pain medications from baseline through the 3-Month Visit 8. Be willing and able to comply with study-related requirements, procedures, and visits Exclusion Criteria: 1. Has a medical, anatomical, and/or psychosocial condition that is contraindicated for commercially available IntellisTM SCS systems as determined by the Investigator 2. Be concurrently participating in another clinical study 3. Has an existing active implanted device such as a pacemaker, another SCS unit, peripheral nerve stimulator, and/or drug delivery pump, etc. 4. Has pain in other area(s) and/or medical condition requiring the regular use of significant pain medications that could interfere with accurate pain reporting, study procedures, and/or confound evaluation of study endpoints, as determined by the Investigator 5. Has mechanical spine instability as determined by the Investigator